We're working hard to transform lung health - from identifying patients earlier to optimizing treatment to accelerating recovery. It's why we're committed to offering a comprehensive suite of technologies tailored for thoracic surgery.
†23 of 32 surveyed after use agreed when compared to surgeon’s primary device.
‡33 of 33 surgeons surveyed after use agreed when compared to surgeon’s primary device.
1. Based on internal report #RE00138840, LIG-45 memo, device length recommendation, thoracic(LF1930T). Feb. 6, 2018.
2. Based on internal test report #RE00125866, Jaw force and gap range burst pressure evaluation of EB4thoracic Maryland device (LF1930T); conducted on bovine tissue. Nov. 20–21, 2017 and Nov. 27–30, 2017.
3. Based on internal test report #RE00134865, Burst pressure verification of pulmonary bovine veins usingthe LigaSure™ LF1930T device. Jan. 17–18, 2018.
4. Based on internal test report #RE00122515, Verification of the LigaSure™ LF1930T device in a GLPchronic hemostasis canine study on pulmonary vasculature. Jan. 8–10, 2018.
5. Based on internal test report #RE00128442, GLP acute pulmonary vasculature hemostasis verificationstudy of the LigaSure™ LF1930T device in hounds. Dec. 8, 2017.
6. LigaSure™ Maryland Jaw Thoracic Sealer/Divider, Nano-Coated [instructions for use]. Boulder, CO:Medtronic; 2017.
7. Based on internal test report #RE00140529 rev A, LigaSure™ Maryland device, nano-coated (LF19XX)tissue testing (memo). March 5, 2018.
8. Based on internal test report #R0035742, Maryland validation, Houston and Los Angeles: independentsurgeon feedback collected during porcine labs. April 16–18 and April 30–May 3, 2013.